0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Immuno-oncology Clinical Trials Market by Design, Phase, Indication - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5674772
UP TO EUR$697USDGBP OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Immuno-oncology Clinical Trials Market grew from USD 6.13 billion in 2023 to USD 6.58 billion in 2024. It is expected to continue growing at a CAGR of 11.17%, reaching USD 12.87 billion by 2030.

Immuno-oncology clinical trials represent a rapidly evolving segment within cancer research focused on leveraging the body's immune system to combat cancer. The scope of these trials includes various cancer types, assessing the safety and efficacy of immunotherapies like checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapy. The necessity for immuno-oncology trials stems from the quest for more targeted therapies with potentially fewer side effects compared to traditional treatments. They are applicable primarily in personalized medicine, offering treatments tailored to specific patient profiles and cancer characteristics. Key end-users of this research include pharmaceutical companies, healthcare providers, and patients seeking advanced treatment options. The market is bolstered by factors such as increasing cancer prevalence, advancements in genomics, and enhanced funding from both public and private sectors. Opportunities abound in expanding clinical trials to diverse populations, thereby ensuring the global applicability of results, and increasing partnerships between biotech firms and academic research institutions to accelerate innovation. However, the market faces challenges such as high trial costs, regulatory complexities, and variable patient responses, which can impede market expansion. Additionally, limited patient enrollment due to stringent selection criteria poses considerable operational hurdles. For innovation and business growth, focus areas include developing combination therapies that enhance immune response and exploring biomarkers that predict patient response, enabling more precise treatment regimens. The market is inherently dynamic, shaped by scientific breakthroughs and evolving regulatory landscapes, with a tendency towards collaborations and strategic alliances as a means to mitigate risks and capitalize on emerging trends. By addressing current limitations and focusing on innovation, stakeholders can better navigate the competitive landscape and drive the effective advancement of immuno-oncology therapeutics.

Understanding Market Dynamics in the Immuno-oncology Clinical Trials Market

The Immuno-oncology Clinical Trials Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising incidence of cancer and the growing adoption of targeted therapy
    • Growing significance of companion diagnostics in drug development
    • Rapidly increasing demand for personalized medicine
  • Market Restraints
    • Requirement of high capital investments and low cost-benefit ratio
  • Market Opportunities
    • Advancements in immuno-oncology testing
    • Increasing financial support from the government for cancer R&D
  • Market Challenges
    • Huge complexity in the production and manufacturing processes

Exploring Porter’s Five Forces for the Immuno-oncology Clinical Trials Market

Porter’s Five Forces framework further strengthens the insights of the Immuno-oncology Clinical Trials Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Immuno-oncology Clinical Trials Market

External macro-environmental factors deeply influence the performance of the Immuno-oncology Clinical Trials Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Immuno-oncology Clinical Trials Market

The Immuno-oncology Clinical Trials Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Immuno-oncology Clinical Trials Market

The Immuno-oncology Clinical Trials Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Immuno-oncology Clinical Trials Market

The Immuno-oncology Clinical Trials Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immuno-oncology Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, BioNTech SE, Bristol Myers Squibb Company, Exscientia PLC, F. Hoffmann-La Roche Ltd., ICON PLC, IO Biotech ApS, IQVIA Inc., Laboratory Corporation of America Holdings, Medpace, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Rubius Therapeutics, Inc., and Syneos Health, Inc..

Market Segmentation & Coverage

This research report categorizes the Immuno-oncology Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Design
    • Expanded Access Trials
    • Interventional Trials
    • Observational Trials
  • Phase
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Indication
    • Hematological Cancer
    • Solid Tumors
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of cancer and the growing adoption of targeted therapy
5.1.1.2. Growing significance of companion diagnostics in drug development
5.1.1.3. Rapidly increasing demand for personalized medicine
5.1.2. Restraints
5.1.2.1. Requirement of high capital investments and low cost-benefit ratio
5.1.3. Opportunities
5.1.3.1. Advancements in immuno-oncology testing
5.1.3.2. Increasing financial support from the government for cancer R&D
5.1.4. Challenges
5.1.4.1. Huge complexity in the production and manufacturing processes
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Immuno-oncology Clinical Trials Market, by Design
6.1. Introduction
6.2. Expanded Access Trials
6.3. Interventional Trials
6.4. Observational Trials
7. Immuno-oncology Clinical Trials Market, by Phase
7.1. Introduction
7.2. Phase I
7.3. Phase II
7.4. Phase III
7.5. Phase IV
8. Immuno-oncology Clinical Trials Market, by Indication
8.1. Introduction
8.2. Hematological Cancer
8.3. Solid Tumors
9. Americas Immuno-oncology Clinical Trials Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Immuno-oncology Clinical Trials Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Immuno-oncology Clinical Trials Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET RESEARCH PROCESS
FIGURE 2. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2023 VS 2030 (%)
FIGURE 7. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET DYNAMICS
TABLE 7. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 29. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 30. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 31. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 33. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 34. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 46. CHINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 47. CHINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 48. CHINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. INDIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 50. INDIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 51. INDIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. JAPAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 56. JAPAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 57. JAPAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. THAILAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 74. THAILAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 75. THAILAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 84. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 85. DENMARK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. EGYPT IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 87. EGYPT IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 88. EGYPT IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. FINLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 90. FINLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 91. FINLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 93. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 94. FRANCE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 96. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 97. GERMANY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 102. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 103. ITALY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. NORWAY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 111. NORWAY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 112. NORWAY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. POLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 114. POLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 115. POLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. QATAR IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 117. QATAR IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 118. QATAR IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 129. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 130. SPAIN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. TURKEY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 138. TURKEY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 139. TURKEY IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 147. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Immuno-oncology Clinical Trials Market, which are profiled in this report, include:
  • AstraZeneca PLC
  • BioNTech SE
  • Bristol Myers Squibb Company
  • Exscientia PLC
  • F. Hoffmann-La Roche Ltd.
  • ICON PLC
  • IO Biotech ApS
  • IQVIA Inc.
  • Laboratory Corporation of America Holdings
  • Medpace, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Rubius Therapeutics, Inc.
  • Syneos Health, Inc.

Methodology

Table Information